Is GLP-1 Worth it?

Is GLP-1 Worth It?
What No One Is Telling You About Ozempic, Your Thyroid & Your Kidneys

GLP-1 receptor agonists are genuinely remarkable. They are also genuinely complicated. Here is the honest, research-grounded picture and what you can do to support your body whether you take them or not.

Watch First

Is it worth trading obesity and diabetes for thyroid cancer and kidney failure?

That question came in through our free Skool community, and I think it deserves a real answer  not a pharmaceutical ad and not a wellness-influencer panic spiral. Both of those are failing people.

GLP-1 receptor agonists,  the class of drugs that includes semaglutide (Ozempic, Wegovy), liraglutide (Victoza), and dulaglutide (Trulicity), are genuinely helping people reverse type 2 diabetes and meaningfully reduce obesity. That is not a small thing. Uncontrolled type 2 diabetes is one of the leading drivers of kidney failure, cardiovascular disease, nerve damage, and early death. For some people, these medications are life-changing and life-saving.

But nature and science almost always come with a catch. The honest picture requires us to sit with that complexity rather than flatten it.

So let us look at what the research actually says about the thyroid and kidney concerns, and then let us talk about something I care about even more: the fact that your body already makes GLP-1 on its own, and that supporting that process naturally is not a consolation prize. It is foundational medicine.

Nausea, constipation, and the gut that just stops moving

Before we even get to the rarer risks, let us talk about the most common ones the ones that make people quietly stop filling their prescription. The most frequently reported side effects of GLP-1 receptor agonists are gastrointestinal: nausea, abdominal pain, diarrhea, ,and the opposite of diarrhea — a complete halt in forward motility. If you have ever experienced gastroparesis, that deep, unmoving fullness that has nothing to do with satisfaction, you already know what I mean.

This happens because GLP-1 slows gastric emptying — that is partly how it works. It is the same mechanism that helps you feel full. But when the system is already sluggish, when the migrating motor complex is already impaired, when there is a history of SIBO or gut dysbiosis, that slowdown can tip into dysfunction. The gut is not a neutral target. It is an ecosystem, and these medications do not operate in a vacuum.

If you are taking a GLP-1 agonist and struggling with GI side effects, supporting your gut terrain is not optional; it is the work. The good news is that it is addressable. Prokinetic botanicals, microbiome support, and targeted prebiotic feeding can meaningfully change how the gut responds to these medications. That is the integrative picture most prescribers are not giving you.

Thyroid cancer: what the rat studies say, and what they don't

Here is the honest starting point: GLP-1 receptor agonists carry an FDA black-box warning for medullary thyroid carcinoma. That warning exists because of preclinical rodent data. In rat and mouse studies, lifetime exposure to GLP-1 agonists was associated with thyroid C-cell hyperplasia, adenomas, and carcinomas, specifically those triggered by GLP-1 receptor activation on parafollicular C-cells.

The important caveat: this signal appears to be species-dependent. GLP-1 receptors are expressed consistently on thyroid C-cells in rodents, but are detected in only roughly 27% of human C-cell tissue. No comparable C-cell proliferative effects were observed in studies of non-human primates. Human thyroid tissue simply does not express the GLP-1 receptor at the density required to make rodents susceptible.

Turning to human data: a large multinational cohort study spanning six population-based databases across Canada, Denmark, Norway, South Korea, Sweden, and Taiwan — nearly 100,000 GLP-1 agonist users — found no increased risk of thyroid cancer compared with users of another diabetes drug class, with a median follow-up of 1.8 to 3.0 years. A separate meta-analysis of randomized controlled trials noted that thyroid cancer is a rare event in clinical trial populations, making definitive conclusions difficult, but did not find consistent evidence of elevated risk. A 2023 French retrospective study found a signal for both medullary and papillary thyroid cancer with long-term GLP-1 use  but it has been extensively critiqued for methodological limitations, and subsequent larger studies have not confirmed the finding.

The FDA maintains the black-box warning  meaning these medications remain contraindicated in people with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2. That is the appropriate conservative clinical stance given the biological plausibility from rodent data, even if human confirmation is lacking. If that profile describes you, the risk calculus is different, and the conversation with your provider is essential.

For everyone else, the short-term human data is more reassuring than the headlines suggest, and there are natural strategies that appear to support thyroid nodule health alongside broader metabolic support. That is worth paying attention to.

Kidney failure: Which direction does the risk actually run?

This is where the framing of the original question, "trading obesity and diabetes for kidney failure," deserves real scrutiny. Because when you look at the evidence, kidney failure is a documented downstream consequence of untreated type 2 diabetes and obesity, not primarily a consequence of the medications that treat them.

Multiple large randomized controlled trial meta-analyses have found that GLP-1 receptor agonists are associated with reduced progression of kidney disease, reduced microalbuminuria, slower decline in glomerular filtration rate, and lower all-cause mortality in patients with diabetes. A 2024 meta-analysis of 19 trials including over 90,000 patients found that GLP-1 agonists were associated with a 19% reduction in the composite primary renal outcome and a 24% reduction in microalbuminuria. Semaglutide was even FDA-approved in 2024 specifically for slowing chronic kidney disease progression in type 2 diabetic patients.

That said, there is a real and clinically documented acute kidney injury risk specifically through dehydration. GLP-1 agonists suppress appetite and slow gastric emptying. In patients who are also experiencing nausea, vomiting, or diarrhea, dehydration can develop rapidly. Inadequate fluid intake while on these medications has been associated with acute kidney injury cases in post-marketing surveillance data, as well as rare cases of acute interstitial nephritis. This is not a theoretical concern — it appears in case reports and pharmacovigilance databases. It is also largely preventable: aggressive hydration support, electrolyte balance, and GI side-effect management significantly reduce this risk.

So the honest answer to the kidney question: GLP-1 agonists, on balance, protect kidneys in diabetic patients — especially when blood sugar is being meaningfully controlled. The kidney risk that does exist is largely a function of poor GI side effect management leading to dehydration. This can be addressed.

Why do we need this medicine in the first place?

This is the part I will not let go of. We do not, by and large, live in famine. The miracles of industrial agriculture and food preservation have solved the problem our ancestors faced  , watching neighbors starve to death through winter. That problem is mostly gone. What replaced it is a food system that has become extraordinarily skilled at harnessing a deep evolutionary drive to eat and store energy and using it to generate profit. Processed food is engineered to override satiety signals. Ultra-processed calorie density is the agricultural equivalent of a supernormal stimulus.

The result is a population with disrupted blood sugar regulation, impaired gut microbiome function, suppressed natural GLP-1 signaling, and a downstream need for a pharmaceutical to restore a hormonal response the body was already designed to produce. That is a remarkable and sobering loop to trace.

I am not saying the medication is wrong. I am saying the medication is a downstream response to an upstream problem — and that understanding the upstream is what gives you real agency over your health.

Your body makes GLP-1. Let's support that.

GLP-1 is produced in the L-cells of your small intestine and colon. It is released every time you eat in response to specific dietary signals ,  and the state of your gut microbiome directly influences how well that release happens. This is not a fringe hypothesis. It is established endocrinology.

Here is what the research consistently shows about naturally supporting GLP-1 signaling:

I also want to name something that gets almost no airtime in these conversations: plant polyphenols  , including curcumin from turmeric and resveratrol,  inhibit DPP-4, the enzyme that degrades endogenous GLP-1. This is the same target that a whole class of diabetes medications (DPP-4 inhibitors, like sitagliptin) acts on. Supporting DPP-4 inhibition through diet is a real mechanism, not wellness speculation. These polyphenols extend the active window of the GLP-1 your body is already producing.

You can have your cake 

If you are taking a GLP-1 receptor agonist and it is helping you function, be present, enjoy your life, and control blood sugar that was genuinely dangerous,  keep taking it. That is the right call, and the evidence supports it for most people. The thyroid cancer signal lives primarily in rat studies, and the kidney failure story is actually a net protective one for diabetic patients when GI side effects are well managed.

If you have a personal or family history of medullary thyroid cancer or MEN2, that is a genuine contraindication and that conversation belongs with your endocrinologist, not a wellness blog.

And if you are taking these medications or trying to support your metabolic health without them, the terrain work is not optional either way. Supporting your gut microbiome, eating fermentable fiber, moving after meals, protecting your sleep, eating protein and fat before carbohydrates: these are not lifestyle add-ons. They are the upstream interventions that either reduce your dependence on medication over time or dramatically improve how well that medication works.

Stable blood sugar is not just about weight. It is about the cognitive clarity and emotional regulation that let you make better decisions — for yourself and for the people who depend on you. That is worth working toward with everything available to you, including the tools that medicine and nature have each provided.

Get your blood sugar stable. You will make better choices from there.

Questions like this one belong in community.

The Gut-Brain Synchrony community is where people with real, complex metabolic and chronic illness questions get grounded, research-backed, integrative answers. It is free to join.

Free forever. No credit card required.

References

1. Bezin J, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023;46(2):384–390. doi:10.2337/dc22-1148
2. Baxter SM, et al. Glucagon-like Peptide 1 receptor agonists and risk of thyroid cancer: An international multisite cohort study. Thyroid. 2025;35(1):69–78. doi:10.1089/thy.2024.0387
3. Silverii GA, et al. GLP-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2024;26(3):891–900. doi:10.1111/dom.15382
4. Bjerre Knudsen L, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151(4):1473–1486. PMC3281535
5. Begum F, et al. Semaglutide-associated kidney injury. Clin Kidney J. 2024;17(9):sfae250. doi:10.1093/ckj/sfae250
6. Pan HC, et al. GLP-1 RAs and cardiovascular and kidney outcomes in type 2 diabetes with acute kidney disease. Nature Communications. 2024. doi:10.1038/s41467-024-50199-y
7. Badve SV, et al. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2025;13(1):15–28. doi:10.1016/S2213-8587(24)00271-7
8. Hira T, et al. Improvement of glucose tolerance by food factors having glucagon-like peptide-1 releasing activity. Int J Mol Sci. 2021;22(12):6623. doi:10.3390/ijms22126623
9. Ohio State University Health. How to activate GLP-1 naturally. 2025. health.osu.edu
10. Grasset E, et al. A specific gut microbiota dysbiosis of type 2 diabetic mice induces GLP-1 resistance through an enteric NO-dependent and gut-brain axis mechanism. Cell Metab. 2017;25(5):1075–1090. doi:10.1016/j.cmet.2017.04.013